Scholarlink

Introduction <p>Dolutegravir (DTG), an integrase strand transfer inhibitor, is recommended as a first-line antiretroviral therapy (ART) for HIV/AIDS in international guidelines. In Japan, approved DTG-containing formulations include the single-agent DTG (Tivicay® tablets) and the fixed-dose combination of DTG, abacavir sulfate, and lamivudine (DTG/ABC/3TC, Triumeq® combination tablets). Although overseas clinical trials have demonstrated the favorable safety and effectiveness of these DTG-containing products, evidence specific to Japanese people living with HIV/AIDS (PLHIV) has remained limited. This report presents the final findings from a decade-long, prospective, post-marketing surveillance of single-agent DTG and DTG/ABC/3TC initiated in 2014.</p> Methods <p>Data on the real-world clinical use of the single-agent DTG and DTG/ABC/3TC were obtained through the HIV-Related Drug Cooperative Survey, a national joint post-marketing program overseen by Japanese manufacturers of HIV therapies. Adverse drug reactions (ADRs) were captured and classified using the Medical Dictionary for Regulatory Activities. Associations between ADR incidence and potential risk factors were examined. Effectiveness was evaluated by longitudinal changes in plasma HIV RNA copy number and peripheral CD4<sup>+</sup> cell counts.</p> Results <p>Among 2345 PLHIV included in the safety analysis, 652 patients (27.80%) reported ADRs. The most frequently reported ADRs were increased blood creatinine (4.78%), abnormal hepatic function (2.43%), and nausea (2.30%). ADR incidence was higher in participants with baseline comorbidities, those receiving concomitant medications, and ART-naïve participants, relative to their counterparts. Notably, no progressive increase in ADR incidence was observed during prolonged use &gt; 2&#xa0;years. Plasma HIV RNA levels demonstrated sustained improvements from baseline in both ART-naïve and ART-experienced participants. By 12&#xa0;months after administration, the proportion of participants achieving plasma HIV RNA levels &lt; 50 copies/ml was about 90% in ART-naïve participants and about 96% in ART-experienced participants. Additionally, CD4<sup>+</sup> T cell counts also demonstrated sustained improvement from baseline in both ART-naïve and ART-experienced participants.</p> Conclusion <p>This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月30日

查看全文
  • Akemi Sebata,
  • Takako Nagao,
  • Tomoko Matsukawa,
  • Yuko Maeno,
  • Miwako Suzuki,
  • Yoichiro Yoshikawa,
  • Shiro Ibe,
  • Akiko Fukuda,
  • Dong Wang

摘要

Introduction

Dolutegravir (DTG), an integrase strand transfer inhibitor, is recommended as a first-line antiretroviral therapy (ART) for HIV/AIDS in international guidelines. In Japan, approved DTG-containing formulations include the single-agent DTG (Tivicay® tablets) and the fixed-dose combination of DTG, abacavir sulfate, and lamivudine (DTG/ABC/3TC, Triumeq® combination tablets). Although overseas clinical trials have demonstrated the favorable safety and effectiveness of these DTG-containing products, evidence specific to Japanese people living with HIV/AIDS (PLHIV) has remained limited. This report presents the final findings from a decade-long, prospective, post-marketing surveillance of single-agent DTG and DTG/ABC/3TC initiated in 2014.

Methods

Data on the real-world clinical use of the single-agent DTG and DTG/ABC/3TC were obtained through the HIV-Related Drug Cooperative Survey, a national joint post-marketing program overseen by Japanese manufacturers of HIV therapies. Adverse drug reactions (ADRs) were captured and classified using the Medical Dictionary for Regulatory Activities. Associations between ADR incidence and potential risk factors were examined. Effectiveness was evaluated by longitudinal changes in plasma HIV RNA copy number and peripheral CD4+ cell counts.

Results

Among 2345 PLHIV included in the safety analysis, 652 patients (27.80%) reported ADRs. The most frequently reported ADRs were increased blood creatinine (4.78%), abnormal hepatic function (2.43%), and nausea (2.30%). ADR incidence was higher in participants with baseline comorbidities, those receiving concomitant medications, and ART-naïve participants, relative to their counterparts. Notably, no progressive increase in ADR incidence was observed during prolonged use > 2 years. Plasma HIV RNA levels demonstrated sustained improvements from baseline in both ART-naïve and ART-experienced participants. By 12 months after administration, the proportion of participants achieving plasma HIV RNA levels < 50 copies/ml was about 90% in ART-naïve participants and about 96% in ART-experienced participants. Additionally, CD4+ T cell counts also demonstrated sustained improvement from baseline in both ART-naïve and ART-experienced participants.

Conclusion

This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice.